Steven Nisticò,1 Piero Campolmi,2 Silvia Moretti,2 Ester Del Duca,3 Nicola Bruscino,2 Rossana Conti,2 Andrea Bassi,2 and Giovanni Cannarozzo3

1Department of Dermatology, University of Rome “Tor Vergata”, Viale Oxford 81, 00133 Rome, Italy
2Department of Dermatology, University of Florence, Florence, Italy
3Laser in Dermatology Unit, University of Rome “Tor Vergata”, Rome, Italy

Flash-lamp pulsed-dye laser (FPDL) is a nonablative technology, typically used in vascular malformation therapy due to its specificity for hemoglobin. FPDL treatmentswere performed in a large group of patients with persistent and/or recalcitrant different dermatological lesions with cutaneous microvessel involvement. In particular, 149 patients (73 males and 76 females) were treated. They were affected by the following dermatological disorders: angiokeratoma circumscriptum, genital and extragenital viral warts, striae rubrae, basal cell carcinoma, Kaposi’s sarcoma, angiolymphoid hyperplasia, and Jessner-Kanof disease. They all underwent various laser sessions. 89 patients (59.7%) achieved excellent clearance, 32 patients (21.4%) achieved good-moderate clearance, 19 patients (12.7%) obtained slight clearance, and 9 subjects (6.1%) had low or no removal of their lesion. In all cases, FPDL was found to be a safe and effective treatment for the abovementioned dermatological lesions in which skin microvessels play a role in pathogenesis or development. Further and single-indication studies, however, are required to assess a standardized and reproducible method for applying this technology to “off-label” indications.

[pdfjs-viewer url=”” viewer_width=100% viewer_height=1360px fullscreen=true download=true print=true]